Furthermore, our in vivo studies with p53/MCA sarcomas demonstrated that using TLR9 agonists in conjunction with radiotherapy significantly outperformed the individual treatments or no treatment in terms of delaying tumor progression. The gene discussed is TLR9; the disease is sarcoma.